A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; Oleclumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 24 Apr 2023 to 15 Feb 2021.
    • 04 Aug 2017 Planned primary completion date changed from 13 Nov 2020 to 15 Feb 2021.
    • 18 Jul 2017 Planned primary completion date changed from 2 Oct 2020 to 13 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top